Previous 10 | Next 10 |
2023-11-20 08:24:45 ET Losers: Syntec Optics Holdings ( OPTX ) -15% . Safe and Green Development Corp ( SGD ) -14% . Plus Therapeutics ( PSTV ) -14% reports new interim reSPECT-GBM phase 2 trial data at the society for NeuroOncology annual meeting. ...
2023-11-20 07:34:54 ET More on Bristol-Myers Bristol Myers Squibb: Bright Future Ahead Bristol-Myers Squibb Company (BMY) Management Presents at Jefferies London Healthcare Conference (Transcript) Bristol-Myers Squibb Company (BMY) Management Presents at 2023 UBS Bio...
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (ide...
2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...
2023-11-15 13:26:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most exciting opportunities can be found in biotech stocks . In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money. Look a...
2023-11-14 15:59:09 ET 2seventy bio, Inc. (TSVT) Q3 2023 Earnings Call Transcript November 14, 2023, 08:00 AM ET Company Participants Elizabeth Hickin - Head of IR Nick Leschly - President and CEO Chip Baird - COO Steve Bernstein - Chief Medical Officer ...
2023-11-14 07:21:31 ET More on 2seventy bio bluebird bio And 2seventy bio - Spinner And Spun: The Better Bet In Cell Therapy 2seventy stock hits new 52-week low on Abecma sales report 2seventy bio stock gains before the bell on job cuts, restructuring Seeking...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...